Arecor Therapeutics PLC Director Dealing (2300B)
June 09 2021 - 2:00AM
UK Regulatory
TIDMAREC
RNS Number : 2300B
Arecor Therapeutics PLC
09 June 2021
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Director Dealing
Cambridge, UK, 9(th) June 2021. Arecor Therapeutics plc (AIM:
AREC) , the biopharmaceutical company advancing today's therapies
to enable healthier lives, today announces the following Directors'
dealings:
Dr Andrew Richards, Non-Executive Chairman, purchased 12,500
ordinary shares of GBP0.01 each in the capital of the Company
("Ordinary Shares") at a price of 242.7 pence per Ordinary
Share.
Christine Soden, Non-Executive Director, purchased 12,500
Ordinary Shares at a price of 242.7 pence per Ordinary Share.
Jeremy Morgan, Non-Executive Director, purchased 20,503 Ordinary
Shares at a price of 242.5 pence per Ordinary Share.
Following the transactions, the total beneficial interest of Dr
Andrew Richards is 217,168 Ordinary Shares, representing 0.78% of
the total voting rights, the total beneficial interest of Christine
Soden is 12,500 Ordinary Shares, representing 0.05% of the total
voting rights and the total beneficial interest of Jeremy Morgan is
20,503 Ordinary Shares, representing 0.07% of the total voting
rights.
-S-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a biopharmaceutical company
transforming patient care by bringing innovative medicines to
market. Through the enhancement of existing medicines using our
Arestat(TM) technology, we are developing a broad portfolio of
therapies as part of our proprietary pipeline and through
partnerships with leading pharmaceutical and biotech companies. Our
treatments for people living with chronic disease are designed to
simplify patient care and improve medication adherence.
For further details please see our website, www.arecor.com
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH
THEM
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Andrew Richards
------------------------------- ----------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Chairman
------------------------------- ----------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Arecor Therapeutics plc
------------------------------- ----------------------------------------
b) LEI 98450093D12I3A8DDD58
------------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-------------------------------------------------------------------------
a) Description of the Ordinary Shares
financial instrument,
type of instrument
------------------------------- ----------------------------------------
b) Identification Code GB00BMWLM973
------------------------------- ----------------------------------------
c) Nature of the transaction Purchase of shares
------------------------------- ----------------------------------------
d) Price(s) and volume(s) 242.7 pence and 12,500 Ordinary Shares
------------------------------- ----------------------------------------
e) Aggregated information
- Aggregated volume
- Aggregated price
------------------------------- ----------------------------------------
f) Date of the transaction 8 June 2021
------------------------------- ----------------------------------------
g) Place of the transaction London Stock Exchange, AIM
------------------------------- ----------------------------------------
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Christine Soden
------------------------------- ----------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------------- ----------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Arecor Therapeutics plc
------------------------------- ----------------------------------------
b) LEI 98450093D12I3A8DDD58
------------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-------------------------------------------------------------------------
a) Description of the Ordinary Shares
financial instrument,
type of instrument
------------------------------- ----------------------------------------
b) Identification Code GB00BMWLM973
------------------------------- ----------------------------------------
c) Nature of the transaction Purchase of shares
------------------------------- ----------------------------------------
d) Price(s) and volume(s) 242.7 pence and 12,500 Ordinary Shares
------------------------------- ----------------------------------------
e) Aggregated information
- Aggregated volume
- Aggregated price
------------------------------- ----------------------------------------
f) Date of the transaction 8 June 2021
------------------------------- ----------------------------------------
g) Place of the transaction London Stock Exchange, AIM
------------------------------- ----------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Jeremy Morgan
------------------------------- ----------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------------- ----------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Arecor Therapeutics plc
------------------------------- ----------------------------------------
b) LEI 98450093D12I3A8DDD58
------------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-------------------------------------------------------------------------
a) Description of the Ordinary Shares
financial instrument,
type of instrument
------------------------------- ----------------------------------------
b) Identification Code GB00BMWLM973
------------------------------- ----------------------------------------
c) Nature of the transaction Purchase of shares
------------------------------- ----------------------------------------
d) Price(s) and volume(s) 242.5 pence and 20,503 Ordinary Shares
------------------------------- ----------------------------------------
e) Aggregated information
- Aggregated volume
- Aggregated price
------------------------------- ----------------------------------------
f) Date of the transaction 8 June 2021
------------------------------- ----------------------------------------
g) Place of the transaction London Stock Exchange, AIM
------------------------------- ----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBLGDLUXGDGBI
(END) Dow Jones Newswires
June 09, 2021 02:00 ET (06:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2024 to May 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From May 2023 to May 2024